Circulating microRNA expression profiles in ovarian cancer

References

• Ahmed FY, Wiltshaw E, Ahern RP, Nicol B, Shepherd J, Blake P et al. 1996. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. Journal of Clinical Oncology 14:2968–2975.
   PubMed Web of Science ®Google Scholar
• Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H et al. 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New England Journal of Medicine 309:883–887.
   PubMed Web of Science ®Google Scholar
• Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O. 2005. Identification of hundreds of conserved and nonconserved human microRNAs. Nature Genetics 37:766–770.
   PubMed Web of Science ®Google Scholar
• Cai H, Yuan Y, Hao YF, Guo TK, Wei X, Zhang YM. 2013. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Medical Oncology 30:452.
   PubMed Web of Science ®Google Scholar
• Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y et al. 2008. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE 3:e2436.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC et al. 2005. CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. International Journal of Gynecological Cancer 15:679–691.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. 2006. Oncomirs – microRNAs with a role in cancer. Nature Reviews Cancer 6:259–269.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences USA 104:15805–15810.
   PubMed Web of Science ®Google Scholar
• Filipowicz W, Bhattacharyya SN, Sonenberg N. 2008. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?Nature Reviews. Genetics 9:102–114.
   PubMed Web of Science ®Google Scholar
• Garcia, M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL et al. 2007. Global cancer facts, figures 2007. Atlanta: American Cancer Society.
   Google Scholar
• Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S et al. 2010. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. British Journal of Cancer 103:693–700.
   PubMed Web of Science ®Google Scholar
• Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK. 2009. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecologic Oncology 114:457–464.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P et al. 2007. MicroRNA signatures in human ovarian cancer. Cancer Research 67:8699–8707.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A et al. 1993. Prevalence screening for ovarian cancer in post-menopausal women by CA-125 measurement and ultrasonography. British Medical Journal 306:1030–1034.
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U. 2004. Progress and challenges in screening for early detection of ovarian cancer. Molecular and Cellular Proteomics 3: 355–366.
   PubMed Web of Science ®Google Scholar
• Kosaka N, Iguchi H, Ochiya T. 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Science 101:2087–2092.
   PubMed Web of Science ®Google Scholar
• Laios A, O’Toole S, Flavin R, Martin C, Kelly L, Ring M et al. 2008. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Molecular Cancer 7:35.
   PubMed Web of Science ®Google Scholar
• Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF et al. 2011. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncology 12:273–285.
   PubMed Web of Science ®Google Scholar
• Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F et al. 2009. A novel and universal method for miRNA RT-qPCR data normalisation. Genome Biology 10:R64.
   PubMed Web of Science ®Google Scholar
• Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH et al. 2008. MicroRNA expression profiles in serous ovarian carcinoma. Clinical Cancer Research 14:2690–2695.
   PubMed Web of Science ®Google Scholar
• Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29:2002–2007.
   Web of Science ®Google Scholar
• Piver MS, Malfetano J, Baker TR, Hempling RE. 1992. Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecologic Oncology 46:357–360.
   PubMedGoogle Scholar
• Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. 2009. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic Oncology 112:55–59.
   PubMed Web of Science ®Google Scholar
• Shih KK, Qin LX, Tanner EJ, Zhou Q, Bisogna M, Dao F et al. 2011. A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecologic Oncology 121:444–450.
   PubMed Web of Science ®Google Scholar
• Tavazoie SF1, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD et al. 2008. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451:147–152.
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C. 2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology 110:13–21.
   PubMed Web of Science ®Google Scholar
• Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N et al. 2009. Fertility preservation in young women with epithelial ovarian cancer. Cancer 115:4118–4112.
   PubMed Web of Science ®Google Scholar
• Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O’Briant K, Godwin AK et al. 2009. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS ONE 4:e5311.
   PubMed Web of Science ®Google Scholar
• Yang HF, Zheng WH, Zhao WT, Guan CY, An J. 2013. Roles of miR-590–miR-55p and miR-590–miR-53p in the development of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Bao (Journal of Southern Medical University) 33:804–811.
   PubMedGoogle Scholar
• Zhang L1, Volinia S, Bonome T, Calin GA, Greshock J, Yang N et al. 2008. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proceedings of the National Academy of Sciences USA 105:7004–7009.
   Google Scholar